ReviewEuropean respiratory review : an official journal of the European Respiratory Society2017
Comorbidities in interstitial lung diseases.
Review in European respiratory review : an official journal of the European Respiratory Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 3 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- Low muscle mass in interstitial lung disease: a systematic review and meta-analysis of prevalence and clinical associations.BMC pulmonary medicine · 2026Pooled it
- Clinical care in interstitial lung disease: a critical appraisal of clinical guidance documents.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- The prevalence of obstructive sleep apnea in interstitial lung disease: a systematic review and meta-analysis.Sleep & breathing = Schlaf & Atmung · 2021Pooled it
- Left Ventricular Diastolic Dysfunction in Patients with Interstitial Lung Disease-A Potential Treatable Trait.Advances in respiratory medicine · 2026Article
- Pulmonary hypertension associated with interstitial lung disease: a state-of-the-art review.The European respiratory journal · 2026Review
- Holistic Management of Pulmonary Fibrosis: A Comprehensive Review.Medicina (Kaunas, Lithuania) · 2026Review
- Review
- Differentiating clinically important interstitial lung abnormalities in lung cancer screening.BMJ open respiratory research · 2025Article
- Article
- Sex-specific aspects in a population of patients undergoing evaluation for interstitial lung disease with transbronchial cryobiopsy.Scientific reports · 2025Article
- Evaluating lung cancer risk factors in adults with interstitial lung disease.Lung cancer (Amsterdam, Netherlands) · 2025Article
- Incidence and clinical impact of coronary artery disease confirmed by coronary CT angiography in patients with interstitial lung disease.BMC pulmonary medicine · 2025Article
- KL‑6, ET‑1 and S100A9 levels in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea.Experimental and therapeutic medicine · 2025Article
- Myeloid PDLIM2 repression as a common mechanism of infection susceptibility in lung diseases.Frontiers in immunology · 2025Article
- Article
- Article
- TheJournal of clinical medicine · 2024Review
- Neurocognitive and Neuropsychiatric Implications of Fibrosing Interstitial Lung Diseases.Biomedicines · 2024Review
- Pulmonary hypertension and lung transplantation waitlist outcomes for hypersensitivity pneumonitis.JHLT open · 2024Article
- Treatment patterns and patient journey in progressive pulmonary fibrosis: a cross-sectional survey.Respiratory research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrosing lung disorders include a large number of diseases with diverse behaviour. Patients can die because of the progression of their illness, remain stable or even improve after appropriate treatment has been instituted. Comorbidities, such as acute and chronic infection, gastro-oesophageal reflux, pulmonary hypertension, lung cancer, cardiovascular diseases, and obstructive sleep apnoea, can pre-exist or develop at any time during the course of the disease and, if unidentified and untreated, may impair quality of life, impact upon the respiratory status of the patients, and ultimately lead to disease progression and death. Therefore, early identification and accurate treatment of comorbidities is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.